Postmarket Study Confirms Benefits of Barricaid Annular Closure Implant

Intrinsic Therapeutics Barricaid Annular Closure

Study results indicate that the use of Intrinsic Therapeutics' Barricaid in high-risk patients results in significantly fewer reherniations and reoperations when compared to patients treated with discectomy alone.

Barricaid is a proprietary technology designed to prevent reherniation and reoperation in patients with large annular defects...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us